Search research articles
Contact Us
Filters
Showing results (141-150 of 149) with videos related to
Page
of 15
Sort By:
You have reached the last page of results.
This site can display upto 149 results.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|
December 29, 2015
[Clinical Study of Non Hodgkin's Lymphoma Treated with Enhanced Chemotherapy Regimen and Increased Treatment Courses]
Xiao-Rong Ma, Yan Xu, Jin Wang, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|
May 8, 2015
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome]
Xiao-Rong Ma, Jin Wang, Wang-Gang Zhang, et al.
World Journal of Gastrointestinal Surgery
|
September 30, 2025
Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial
Xian Qin, Jing Chen, Hua-Ni Zhang, et al.
Stem Cell Reviews and Reports
|
January 24, 2020
Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy
Lulu E Yan, Hongyu Zhang, Masayuki Wada, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
October 6, 2022
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA
Liu-Fang Ye, Zi-Yao Huang, Xiao-Xi Chen, et al.
Biomolecules
|
September 28, 2021
The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
Liu-Fang Ye, Xiao-Meng Ji, Chao Ren, et al.
Journal of Medical Case Reports
|
December 10, 2022
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, et al.
Journal of Hematology & Oncology
|
December 22, 2018
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, et al.
Journal of Hematology & Oncology
|
July 6, 2022
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, et al.
Page
of 15
Search research articles
Search
Showing results (141-150 of 149) with videos related to
Sort By:
Page
of 15
You have reached the last page of results.
This site can display upto 149 results.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|
December 29, 2015
[Clinical Study of Non Hodgkin's Lymphoma Treated with Enhanced Chemotherapy Regimen and Increased Treatment Courses]
Xiao-Rong Ma, Yan Xu, Jin Wang, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|
May 8, 2015
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome]
Xiao-Rong Ma, Jin Wang, Wang-Gang Zhang, et al.
World Journal of Gastrointestinal Surgery
|
September 30, 2025
Treatment of human umbilical cord-derived mesenchymal stem cells for hepatitis B virus-associated decompensated liver cirrhosis: A clinical trial
Xian Qin, Jing Chen, Hua-Ni Zhang, et al.
Stem Cell Reviews and Reports
|
January 24, 2020
Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy
Lulu E Yan, Hongyu Zhang, Masayuki Wada, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|
October 6, 2022
Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA
Liu-Fang Ye, Zi-Yao Huang, Xiao-Xi Chen, et al.
Biomolecules
|
September 28, 2021
The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis
Liu-Fang Ye, Xiao-Meng Ji, Chao Ren, et al.
Journal of Medical Case Reports
|
December 10, 2022
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report
Bai-Yan Wang, Wan-Hong Zhao, Yin-Xia Chen, et al.
Journal of Hematology & Oncology
|
December 22, 2018
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao, Jie Liu, Bai-Yan Wang, et al.
Journal of Hematology & Oncology
|
July 6, 2022
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Wan-Hong Zhao, Bai-Yan Wang, Li-Juan Chen, et al.
Page
of 15